Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms
- PMID: 23633486
- DOI: 10.1158/0008-5472.CAN-12-4115
Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms
Abstract
Tumors can suppress the host immune system by employing a variety of cellular immune modulators, such as regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells (MDSC). In the peripheral blood of patients with advanced stage melanoma, there is an accumulation of CD14(+)HLA-DR(lo/-) MDSC that suppress autologous T cells ex vivo in a STAT-3-dependent manner. However, a precise mechanistic basis underlying this effect is unclear, particularly with regard to whether the MDSC induction mechanism relies on cell-cell contact of melanoma cells with CD14(+) cells. Here, we show that early-passage human melanoma cells induce phenotypic changes in CD14(+) monocytes, leading them to resemble MDSCs characterized in patients with advanced stage melanoma. These MDSC-like cells potently suppress autologous T-cell proliferation and IFN-γ production. Notably, induction of myeloid-suppressive functions requires contact or close proximity between monocytes and tumor cells. Further, this induction is largely dependent on production of cyclooxygenase-2 (COX-2) because its inhibition in these MDSC-like cells limits their ability to suppress T-cell function. We confirmed our findings with CD14(+) cells isolated from patients with advanced stage melanoma, which inhibited autologous T cells in a manner relying up prostaglandin E2 (PGE2), STAT-3, and superoxide. Indeed, PGE2 was sufficient to confer to monocytes the ability to suppress proliferation and IFN-γ production by autologous T cells ex vivo. In summary, our results reveal how immune suppression by MDSC can be initiated in the tumor microenvironment of human melanoma.
©2013 AACR.
Similar articles
-
Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity.Clin Cancer Res. 2014 Aug 1;20(15):4096-106. doi: 10.1158/1078-0432.CCR-14-0635. Epub 2014 Jun 6. Clin Cancer Res. 2014. PMID: 24907113
-
Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.Exp Dermatol. 2014 Mar;23(3):202-4. doi: 10.1111/exd.12336. Exp Dermatol. 2014. PMID: 24495013
-
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.Cancer Res. 2006 Sep 15;66(18):9290-8. doi: 10.1158/0008-5472.CAN-06-1819. Cancer Res. 2006. PMID: 16982774
-
Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):721s-726s. doi: 10.1158/1078-0432.CCR-06-2197. Clin Cancer Res. 2007. PMID: 17255300 Review.
-
Antigen specificity of immune suppression by myeloid-derived suppressor cells.J Leukoc Biol. 2011 Jul;90(1):31-6. doi: 10.1189/jlb.0111021. Epub 2011 Apr 12. J Leukoc Biol. 2011. PMID: 21486906 Review.
Cited by
-
The changes of angiogenesis and immune cell infiltration in the intra- and peri-tumoral melanoma microenvironment.Int J Mol Sci. 2015 Apr 9;16(4):7876-89. doi: 10.3390/ijms16047876. Int J Mol Sci. 2015. PMID: 25913374 Free PMC article.
-
Crosstalk between angiogenesis and immune regulation in the tumor microenvironment.Arch Pharm Res. 2022 Jun;45(6):401-416. doi: 10.1007/s12272-022-01389-z. Epub 2022 Jun 27. Arch Pharm Res. 2022. PMID: 35759090 Free PMC article. Review.
-
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.Int J Mol Sci. 2021 Dec 10;22(24):13311. doi: 10.3390/ijms222413311. Int J Mol Sci. 2021. PMID: 34948104 Free PMC article. Review.
-
The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.Front Immunol. 2013 Dec 2;4:419. doi: 10.3389/fimmu.2013.00419. Front Immunol. 2013. PMID: 24348482 Free PMC article. Review.
-
NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells.Cancer Immunol Immunother. 2020 Oct;69(10):2147-2155. doi: 10.1007/s00262-020-02615-7. Epub 2020 May 28. Cancer Immunol Immunother. 2020. PMID: 32468232 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous